The algorithms for treating psoriatic arthritis (PsA) are unique among rheumatic diseases because most PsA patients receive prior treatment by dermatologists for psoriasis, with many of the same therapies that are frequently used for PsA. Therefore, biological and targeted synthetic DMARDs are more frequently used as early-line therapies after the diagnosis of PsA. Understanding the use of non-TNF inhibitors, namely, IL-12/23 inhibitors, IL-17 inhibitors, PDE-4 inhibitors, JAK inhibitors, and co-stimulatory modulators, is crucial for pharmaceutical companies to properly manage their brands in the PsA market. Analysis of claims data and electronic health records provides an objective lens to see how physicians prescribe therapies and what the clinical profiles of treated patients are.
· What is the patient share in PsA for IL-17 inhibitors and other key segments?
· What are the demographic characteristics and clinical profiles of PsA patients on Otezla and Xeljanz?
· What are the key risk factors, comorbidities, and co–prescribed/additional therapies by patient segment for PsA?
· How do patient cohorts for PsA compare in care utilization and outcomes (physician visits and other healthcare encounters)?
· What are the reimbursed and out-of-pocket costs?
· What insurance type do PsA patients have?